Regenics’ idea is to locally revive the regenerative abilities of skin cells in order to improve wound healing by the use of extracts from salmon eggs. 

Regenics is developing medical device wound healing products, for CE-marking under class IIa, IIb or III, dependant on final claims. Regenics also develops a wound debridement drug. The technology is  based on extensive purification of cytoplasmic fraction of salmon roe, gene expression technology and patented in US, EU and RoW



Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.